Skip to content

Clinical trials

Phase 3 Esophageal Squamous Cell Carcinoma trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Esophageal Squamous Cell Carcinoma Phase: Phase 3 Clear all

64 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20021
20071
20081
20091
20102
20111
20123
20146
20153
20161
20171
20186
20195
20205
20212
20225
20233
20245
20253
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed21
Recruiting15
Unknown status14
Not yet recruiting5
Active, not recruiting4
Terminated4
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fudan University7
Sun Yat-sen University6
The First Affiliated Hospital of Henan University of Science and Technology6
BeiGene3
Henan Cancer Hospital3
Merck Sharp & Dohme LLC2
Radiation Therapy Oncology Group2
Sichuan Cancer Hospital and Research Institute2
Tianjin Medical University Cancer Institute and Hospital2
AIO-Studien-gGmbH1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Esophageal Squamous Cell Carcinoma64
Esophageal Neoplasms16
Carcinoma, Squamous Cell2
Neoplasm Metastasis2
Basal Cell Carcinoma1
Carcinoma, Hepatocellular1
Carcinoma, Merkel Cell1
Carcinoma, Renal Cell1
Carcinoma, Transitional Cell1
Endometrial Neoplasms1

Trials

Showing 1 to 25 of 64. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.